Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer (ChIP-Seq)
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 38 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 38 samples: 37 distinct titles, 1 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancerNature genetics · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE255132_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1073576 and SRA study SRP488340. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 38 sample titles: 37 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8064564 VCaP_DMSO_H3K27ac
- GSM8064565 VCaP_CBPD_4hrs_H3K27ac
- GSM8064566 VCaP_GNE_4hrs_H3K27ac
- GSM8064567 VCaP_CCS_4h_H3K27ac
- GSM8064568 VCaP_DMSO_AR
- GSM8064569 VCaP_CBPD_4h_AR
- GSM8064570 VCaP_GNE_4h_AR
- GSM8064571 VCaP_DMSO_FOXA1
- GSM8064572 VCaP_CBPD_4h_FOXA1
- GSM8064573 VCaP_GNE_4h_FOXA1
- GSM8064574 VCaP_DMSO_H2BK5ac
- GSM8064575 VCaP_CBPD_4hrs_H2BK5ac
- GSM8064576 VCaP_GNE_4hrs_H2BK5ac
- GSM8064577 VCaP_DMSO_H2BK20ac
- GSM8064578 VCaP_CBPD_4hrs_H2BK20ac
- GSM8064579 VCaP_GNE_4hrs_H2BK20ac
- GSM8064580 VCaP_P300
- GSM8064581 VCaP_DMSO_BRD4
- GSM8064582 VCaP_MED1_AM
- GSM8064583 VcaP_DMSO_Pol2
- GSM8064584 VcaP_CBPD_4h_Pol2
- GSM8064585 VcaP_GNE_4h_Pol2
- GSM8064586 VCaP_DMSO_H3K18ac
- GSM8064587 VCaP_CBPD_4hrs_H3K18ac
- GSM8064588 VCaP_GNE_4hrs_H3K18ac
- GSM8064589 VCaP_DMSO_D28_ERG_CST
- GSM8064590 DMSO_AR
- GSM8064591 DMSO_FOXA1
- GSM8064592 AU15330_AR
- GSM8064593 AU15330_FOXA1
- GSM9056440 VCaP_H2BK20ac_CST
- GSM9056441 DU145_H2BK20ac_CST
- GSM9056442 PC3_H2BK20ac_CST
- GSM9056443 VCaP_H2BK16ac_abcam
- GSM9056444 DU145_H2BK16ac_abcam
- GSM9056445 PC3_H2BK16ac_abcam
- GSM9056446 VCaP_DMSO_BRD4
- GSM9056447 VCaP_CBPD_4h_BRD4_Diagenode
- GSE255134 Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer 76 samples shares p300, h2b, cbp, enhanceosomes, degradation, acetylated, targeting, prostate
- GSE255133 Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer (RNA-Seq) 32 samples shares p300, h2b, cbp, enhanceosomes, degradation, acetylated, targeting, prostate
- GSE296236 Targeting p300/CBP abolishes HOXB13 loss-induced lipogenesis and tumor metastasis [ChIP-seq] 15 samples shares p300, cbp, targeting
- GSE275777 AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer [ChIP-seq] 13 samples shares p300, cbp, prostate
- GSE237043 Targeting Dependency on a Paralog Pair of CBP/p300 against De-repression of KREMEN2 in SMARCB1-Deficient Cancers 60 samples shares p300, cbp, targeting
- GSE296250 Targeting p300/CBP abolishes HOXB13 loss-induced lipogenesis and tumor metastasis 43 samples shares p300, cbp, targeting
- GSE296237 Targeting p300/CBP abolishes HOXB13 loss-induced lipogenesis and tumor metastasis [RNA-seq] 28 samples shares p300, cbp, targeting
- GSE275778 AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer [RNA-seq: 22RV1] 20 samples shares p300, cbp, prostate
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.